Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.30 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21226029 | 1.00 | MEN1 (0.35) | MEN1KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL19034621 | 0.93 | NR1I2 (0.34) | MEN1KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL6288677 | 0.86 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL19133452 | 0.85 | — | — | |
| SCHEMBL10491832 | 0.85 | MEN1 (0.35) | MEN1KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL6051022 | 0.80 | LMNA (0.37) | MEN1KMT2AALDH1A1LMNAGBA1 | |
| SCHEMBL11693648 | 0.79 | LMNA (0.32) | MEN1KMT2ALMNA | |
| SCHEMBL9819240 | 0.77 | CYP2D6 (0.34) | ALDH1A1 | |
| SCHEMBL27771509 | 0.76 | NR1I2 (0.36) | MEN1KMT2AGNAI3GNAO1GNAI1 | |
| SCHEMBL22871231 | 0.73 | LMNA (0.36) | MEN1KMT2AGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11246933-B1 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11246933-B1 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | MEN1 2092/4885KMT2A 4005/4885GNAI3 2702/4885 |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | MEN1 2092/4885KMT2A 4005/4885GNAI3 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.